Kidney Cancer Weekly

September 17, 2025

Videos

Peer-to-Peer Clinical Conversations

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell RCC - Vitaly Margulis

Joseph Prijdekker

Zachary Klaassen and Vitaly Margulis explore the emerging role of Girentuximab PET-CT in kidney cancer management.

View

Combination HIF-2α/VEGF Dual Inhibition in Refractory Clear Cell RCC - Michael Serzan

Pedro Barata discusses kidney cancer data with Michael Serzan regarding the combination of Casdatifan (AB-521), a HIF-2 alpha inhibitor, with cabozantinib for treatment-refractory clear cell RCC.

View

Beyond the Abstracts

Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma - Beyond the Abstract

Metastatic Renal Cell Carcinoma: Synchronous vs. Metachronous Metastatic Disease and Its Impact on Cancer Control in the IO-Combination Era-Real World Experiences from a Multi-Institutional Cohort - Beyond the Abstract

Conference Coverage

SCS AUA 2025: Contemporary Outcomes for Radical Nephrectomy with Inferior Vena Cava Thrombectomy in the Era of Pre-Operative Immunotherapy

ASCO 2025: STARLITE 2: Phase 2 Study of Nivolumab plus 177lutetium-Labeled Anti–carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ASCO 2025: Biomarkers in Kidney Cancer: Are We There Yet?

ASCO 2025: Targeting HIF-2α: A New Frontier in Renal Cell Cancer Therapy

ASCO 2025: Functional Imaging in Renal Cell Carcinoma: Enhancing Diagnosis and Treatment Strategies

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Machine learning model in multi-omics perspective demystifies the prognostic significance of crotonylation heterogeneity in clear cell renal cell carcinoma.

Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).

Case Report: Successful delivery following chemotherapy in a pregnant patient with metastatic SMARCB1-deficient renal medullary carcinoma.

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling.

Camera Port Swapping in Transperitoneal Robotic Partial Nephrectomy: A Feasible Alternative to the Retroperitoneal Approach for Posterior Renal Tumors.

End-of-life and palliative care in patients with metastatic renal cancer.

Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.

Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the Kidney.

Is Preoperative Anticoagulation in Nephrectomy with Caval Thrombectomy Necessary? A Multicenter Retrospective Cohort Study.

Lipid metabolism of clear cell renal cell carcinoma predicts survival and affects intratumoral CD8 T cells.

Management of renal cancer with inferior vena cava extension over 30 years: a bi-centric study.

The Safety Profile of Belzutifan in Renal Tumors: Real-World Data from a Tertiary Academic Center.

The Nephrologist's Perspective in Evaluation and Management of Localized Renal Masses: Core Curriculum 2025.

Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer.

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login